
De-risking prostate cancer screening with ClarityDX Prostate
ClarityDX Prostate builds upon the utility of clinical features and blood-based biomarkers to determine a patient’s risk of having aggressive prostate cancer. This empowers patients and their healthcare providers make more informed healthcare decisions.

Dr. John Lewis
CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta
Recent news
CUA 2026 ePoster Understanding urologists perspectives on using an AI-enabled decision support tool in healthcare
CUA2026_eposter Understanding urologists’ perspectives on using an AI-enabled decision [...]
Progress in prostate cancer screening: Generous philanthropy led to the creation of an innovative prostate cancer test
Generous philanthropy led to the creation of an innovative [...]
Nanostics is recognized as a global honoree of the Aim2Flourish 2026 Flourish Prize
We are honored to see Nanostics recognized as a [...]
2024 Prostate cancer screening update
Our success is possible thanks to the support of our many Canadian and international collaborators, funders, and partners.




















